加载中
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
前收盘价
US$23.68
+US$0.78 · +3.41%
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
45
合理估值
情绪
49
多空交织
风险
54
风险偏高
动量
70
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
日内区间
当前US$23.68
52周区间
当前US$23.68
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（EUR） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2964.3万 EUR | −719万 EUR | 3620.8万 EUR | 477.6万 EUR | 264.7万 EUR |
| 毛利 | 2964.3万 EUR | −719万 EUR | 3620.8万 EUR | 477.6万 EUR | 264.7万 EUR |
| 研究与开发 | 2311.5万 EUR | 4054.1万 EUR | 3839.6万 EUR | 3263.6万 EUR | 3037.8万 EUR |
| 销售、一般及管理费用 | 2022.2万 EUR | 2052.7万 EUR | 2204.9万 EUR | 1785.7万 EUR | 1943.4万 EUR |
| 营业费用 | 4046.1万 EUR | 6120.2万 EUR | 6298.7万 EUR | 5147.8万 EUR | 5522.6万 EUR |
| 利息收入 | 98.5万 EUR | 262.9万 EUR | 121.7万 EUR | 25.6万 EUR | — |
| 利息支出 | 1039.5万 EUR | 808.6万 EUR | 798.2万 EUR | 583.7万 EUR | 69.95万 EUR |
| 折旧和摊销 | 149.5万 EUR | 162.1万 EUR | 151.3万 EUR | 150万 EUR | 156万 EUR |
| 营业利润 | −1081.8万 EUR | −6839.2万 EUR | −2677.9万 EUR | −4670.2万 EUR | −5257.9万 EUR |
| 净利润 | −2396.1万 EUR | −6813.2万 EUR | −3970万 EUR | −5704.1万 EUR | −4700.3万 EUR |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
评级样本有限，仅4项
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
